Journal of International Psychiatry

Major depressive disorder (MDD) is a complex and disabling mental disorder with persistent low mood, interest and slow thinking, which may cause a decline in quality of individual life and may cause harm to themselves and others. However, the current diagnosis and treatment lack of convenient and reliable objective diagnosis and efficacy prediction tools, which is easy to lead to misdiagnosis and ineffective treatment. Indicators of peripheral proteins and neuroimaging have become candidate biomarkers due to the convenience and small trauma for the examination methods, making it possible to objectively predict, diagnose and monitor the therapeutic effect of MDD. In this paper, we summarized the peripheral blood protein and neuroimaging biomarkers involved in main pathogenesis of MDD, and sketched out the imaging proteomics which organically combine the peripheral protein and neuroimaging. And to explore the potential as a tool for objective diagnosis and curative effect prediction in order to provide a new method for reasonable diagnosis and effective treatment.

major depressive disorder; biomarker; peripheral proteins; imaging; imaging proteomics